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http://dx.doi.org/10.1016/j.gmitIn the past decade, about half a dozen
books have been published that are very
critical of the pharmaceutical industry,
some of them scathingly so. They include
Merrill Goozner’s The $800 Million Pill, Jerry
Avorn’s Powerful Medicines, John Aramson’s
Overdosed America, Jerome Kassirer’s On
the Take, Marcia Angell’s The Truth About
the Drug Companies, and, very recently, Ben
Goldacre’s Bad Pharma. From various angles,these books provide an unﬂatteringdsometimes disturbingdbut
consistent portrait of drug companies’ behaviors.
The seeming deluge of these books on a similar topic cannot be
dismissed offhand as a pharma-bashing fad, because these books
appear to be well researched and based on credible sources. A
few of them arewritten by former editors of some prestigious med-
ical journals who witnessed ﬁrsthand some high-proﬁle cases of
clinical trials sponsored by the industry, such as the Vioxx saga.
One troubling behavior is the selective publication and the suppres-
sion of “negative” information arising from clinical trials funded by
drug companies.
Against this foreground is the enactment of several legislations in
the United States (U.S.) mandating more openness in clinical trials
and the birth of a handful of clinical trial registries. Notably, Section
113 of the Food and Drug AdministrationModernization Act (FDAMA
113) was enacted by the U.S. Congress in 1997. Section 113 ultimately
led to the creation of ClinicalTrials.gov as an Internet-based public
depository for information on studies of drugs (including biological
compounds) that are conducted under the FDA’s investigational
new drug regulations.1 In 2007, the U.S. Congress enacted the FDA
Amendments Act of 2007 (FDAAA), or Public Law 110-85. On the
same day, the FDA Revitalization Act was signed into law, with the
aim of improving the FDA’s ability to ensure the safety of the nation’s
drugs and medical devices. Section 801 of the FDAAA mandates the
expansion of ClinicalTrials.gov and provides for the ﬁrst federally
funded trial results database. These legislations and trial registries
are intended to encourage and promote openness in clinical trials.
As elaborated in these books, the selective reporting and the
suppression of “negative” data are quite ubiquitous and pervasive
across the entire industry. Not surprisingly, endometriosis trials
are no exception. In a survey conducted 4 years ago, it was found
that 57 endometriosis-related clinical trials were registered at Clin-
icalTrials.gov.2 Among the 15 completed Phase II or Phase III trials
that evaluated the efﬁcacy of various promising compounds, only
three (20%) had published their results, but the remaining 12
(80%) did not. In other words, most endometriosis trials were
shrouded in secrecy.tter Copyright2013,TheAsia-PaciﬁcAssociation forGynecologicEn
.2013.05.007Four years have since passed. A recent analysis of trials regis-
tered at ClinicalTrials.gov found that the situation has changed
very little.3 Speciﬁcally, it reports that among 35 completed trials
on endometriosis, only 11 (31.4%) published their results, which is
below the 66.3% reported in a recent survey of nonendometriosis
trials.3 More disturbingly, trials sponsored by industry were about
four times less likely than those sponsored by nonindustry to pub-
lish the results, even though they were typically larger in size and
completed quickerdlikely because of more resources. Industry-
sponsored trials that did get published were those that led to the
regulatory approval for marketing. Conspicuously, no “negative”
trials sponsored by industry have ever been published. Such an
abject failure to publish and selective reporting pose a serious
threat to professional access to all trial results and to the validity
of evidence-based medicine. It also goes against the mounting
pressure around the globe for greater transparency of clinical trials.
One can argue that the ultimate goal of disease-focused research
such as endometriosis research is better clinical care of patients
through providing better diagnosis, treatment, or even innovative
ways of prevention. Toward this goal, one important intermediate
linking basic research and clinical practice is randomized clinical
trials that evaluate the safety and efﬁcacy of compounds deemed
to be promising in preclinical research. Results from successful clin-
ical trials may also be submitted to regulatory agencies to obtain
approval for marketing.
Clinical trials are known to contribute to our knowledge base in
evidenced-based medicine. Yet, this hinges critically on the timely
public release and dissemination of ﬁndings from such trials, which
are considered to be key principles in the proper conduct of clinical
research.4 Indeed, clinicians, policymakers, and even patients learn
of evidence-based medicine primarily through peer-reviewed
biomedical journals. The apparent opaqueness of endometriosis tri-
als is certainly a disservice to the public.
At the time when there is a palpable disappointment over the
slow progress in developing novel therapeutics for endometriosis,5
this opaqueness is an added hindrance to drug development,
because it impacts negatively on basic research scientists. When
everybody is holding their cards close to their chests, nobody will
beneﬁt from hard-earned lessons, and everybody will be con-
demned to repeat others’ mistakes, miscalculations, or missteps.
It also exposes trial participants to the unnecessary risk of receiving
inferior treatment or having an adverse effect since different drug
companies may test slightly different drugs that belong to the
same class of drug (such as selective progesterone receptor modu-
lators). Above all, it betrays the wish implicitly or tacitly expressed
by the trial participants that their participationwill generate gener-
alizable medical knowledge that might beneﬁt not only themselvesdoscopyandMinimally InvasiveTherapy. PublishedbyElsevier TaiwanLLC.All rights reserved.
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collectively the trial and other scientiﬁc research will ultimately
improve patient care.
Given this apparent opaqueness in endometriosis trials, pres-
sure needs to be kept on to change this situation. More transpar-
ency not only is a moral imperative to researchers, sponsors,
reviewers, and journal editors alike, but also should help re-
searchers, healthcare providers, policy-makers, drug companies
and, above all, patients with endometriosis.References
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